Founded by Anastasia Khvorova, PhD and Alexey Wolfson, PhD in 2007 to develop new nucleic acids- based technologies for therapeutic and research use. Advirna is a private biotechnology company developing innovative solutions for efficient delivery of polynucleotides in vivo. Advirna’s self-deliverable RNAi platform technology is based on the recent breakthroughs in oligonucleotide chemistry, which allows efficent delivery delivery of chemically synthesized oligonucleotides (siRNA, ASO) to all cell types in vitro and targeted delivery to tissues and organs in vivo.
Advirna is providing "self-deliverable" siRNA conjugates (sdRNAs) for research and therapeutic development purposes. sdRNAs are fully chemcially modified siRNAs attached to a variety of ligands for cell penetration and in vivo delivery. Validated Self-deliverable siRNAs are guaranteed to knockdown gene expression. Transfection Controls are available to validate the technology for your specific experimental system (cell line, tissue model, etc.) for uptake efficiency and gene knockdown. Products are available in mutiple formats (validated, guaranated to work compounds from the catalog, custom-designed validated sdRNAs, non-validated sdRNA pools, "in-vivo quality" sdRNAs specifically designed for in vivo experiments).
Advirna performs pathway-wide RNAi and ASO screens for identification target gene functions
Advrina performs siRNA and ASO therapeutic lead identification projects by extensive screens of oligonucleotide compounds.
Syntheis of modifeid oligonucleotides such as siRNAs and ASOs
Advirna provides a variety of services requiring the use of molecular bilogical and biochemical techniques and assays, such as gene expression (qPCR, bDNA), ELISA, HPLC, etc. and cell-based functional assays
Advirna has not received any reviews.
Advirna has not received any endorsements.